亞盛醫藥
AscentageHKHKDAscentage (US:ASPHF) — Biotechnology. Number of exchanges where the company shares trade: 2. On this page — price and chart, dividends, top holders and share count history.
About the company
- Website
- ascentage.cn
- Investor relations
- ascentage.cn/investor-relations/
- Sector
- Healthcare · Biotechnology
- Headquarters
- Suzhou, China
- Management
- Dajun Yang
- Employees
- 828
- Shares outstanding
- Free float
- 286.13 M
- Market cap
- 10.96 B HKD
- Insiders
- 10.88%
- Institutions
- 17.48%
- Legal form
- 4XP8
- ISIN
- KYG0519B1023
- LEI
- 300300WBVGZIXEF27W64
- P/EP/E (Price / Earnings) — how many years of the company's profit you pay for a share. Calculated: current price ÷ net earnings per share over the last 12 months. Lower means cheaper relative to profit. Not calculated when the company has a loss (—).
- loss
- EPSEPS (Earnings Per Share) — the company's net profit over the last 12 months divided by the number of its shares, in the currency of this listing. A negative value (red) means a loss. P/E is the share price divided by EPS.
- −0.56 USD
- |P/B (price to book) — share price ÷ shareholders' equity per share from the latest balance sheet. Graham — as Benjamin Graham counted it: equity without goodwill, other intangible assets and preferred stock, that is tangible book value. He considered up to 1.5 acceptable for a defensive investor (green), or a product P/E × P/B up to 22.5. With negative tangible equity, Graham's P/B is not calculated.
- 17.019.1
- FCFFCF (Free Cash Flow) — money left to the company after operating costs and investment in equipment; dividends are safest when paid from it. Calculated: operating cash flow − capital expenditure, over the last 12 months, in the reporting currency.
- −1.34 B CNY
- DebtDebt — all loans and bonds of the company per the latest report (short- and long-term), in the reporting currency. Below — how many years the company would need to repay net debt (debt minus cash) from its free cash flow: net debt ÷ FCF. Up to 3 years — good, 3–6 — moderate, over 6 — high. «Net cash» — net debt is negative.
- 2.09 B CNYnegative FCF — not covered
- Earnings and FCF — for the 12 months to 30.06.2026 (the company's latest report).
- NAVNAV — net asset value by the balance sheet: the company's assets minus its liabilities, the share of the company's shareholders (without other owners' stakes in its subsidiaries). Shown per share, with P/NAV — how many times the share price exceeds NAV per share (below 1 — the share costs less than its net assets on the balance sheet). Click to see what NAV is made of and its history.
Description
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has strategic partnership with biotechnology and pharmaceutical companies; research institutions; and Peking University to build a collaborative system for hematological oncology. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
Top holders
| Holder | Stake | Shares | Report date |
|---|---|---|---|
| Yang (Dajun) (Chief Exec… | ≈6.15% | 23.15 M | 2024-12-27 |
| Zhai (Yifan) (Divisional… | ≈3.79% | 14.26 M | 2024-12-27 |
| Wang (Shaomeng) (Directo… | ≈2.67% | 10.05 M | 2024-12-27 |
| VANGUARD STAR FUNDS-Vang… | 1.05% | 3.95 M | 2026-07-31 |
| VANGUARD Intl Eqy. INDEX… | 1.05% | 3.93 M | 2026-07-31 |
| iShares, Inc.-iShares Co… | 0.92% | 3.46 M | 2026-09-30 |
| VANGUARD Intl Eqy. INDEX… | 0.32% | 1.21 M | 2026-07-31 |
| iShares Trust-iShares Co… | 0.15% | 566 000 | 2026-09-30 |
| SPDR INDEX SHARES Fd.S-S… | 0.06% | 231 200 | 2026-09-30 |
| VANGUARD Intl Eqy. INDEX… | 0.05% | 204 400 | 2026-07-31 |
| Fidelity Salem Street Tr… | 0.05% | 183 578 | 2026-08-31 |
| SPDR-EUROPE-SSgA SPDR ET… | 0.03% | 116 800 | 2026-09-30 |
| iShares Trust-iShares MS… | 0.03% | 115 100 | 2026-09-30 |
| Lippman (Marc E) (Indepe… | ≈0.01% | 21 174 | 2025-05-23 |
Sign in with Google